24 Oct 2024 Avacta Reports Pipeline Advances with Two Novel Programs at the EORTC-NCI-AACR Molecular Targets Symposium in Barcelona Investors | Therapeutics
21 Oct 2024 Avacta and Tempus Enter Strategic Collaboration to Advance AI-Driven Drug Development in Oncology Investors | Therapeutics
17 Oct 2024 Avacta Expands its Pipeline with Two Novel Assets Developed Using its pre|CISION® Platform Investors | Therapeutics
15 Oct 2024 Avacta Group strengthens executive team with appointment of Michelle Morrow, PhD as Chief Scientific Officer Investors | Therapeutics
10 Oct 2024 Avacta to Unveil Pipeline Expansion and Novel, Next-Generational Targeted Cancer Therapy Programs at 2024 EORTC-NCI-AACR Symposium Investors | Therapeutics
24 Sep 2024 ESMO poster data video presentation by Christina Coughlin Investors | Podcasts and Videos | Therapeutics
14 Sep 2024 Avacta Reports Updated Phase 1 Clinical Data of AVA6000 at the European Society for Medical Oncology (ESMO) Congress Demonstrating Multiple Ongoing, Durable Responses in Solid Tumors Investors | Therapeutics
11 Sep 2024 Research & Development Spotlight Series – Episode 5 Blogs | Investors | Podcasts and Videos | R&D Spotlights Series | Therapeutics
09 Sep 2024 Avacta to present updated clinical data on AVA6000 at the European Society for Medical Oncology (ESMO) Congress Investors | Therapeutics